奥西默替尼
医学
肺癌
表皮生长因子受体
肿瘤科
内科学
酪氨酸激酶
突变
癌症
受体
埃罗替尼
基因
遗传学
生物
作者
Yangyang Cai,Yizhuo Wang,Jian Sun,Xu Wang,Yinghui Xu,Chao Sun,Ye Guo,Mengyao Sun,Kewei Ma
标识
DOI:10.1177/0300060520928793
摘要
The discovery of epidermal growth factor receptor (EGFR) somatic mutations and the availability of tyrosine kinase inhibitors (TKIs) as targeted therapies have altered the therapeutic prospects of advanced non-small-cell lung cancer (NSCLC). G719X and S768I are uncommon mutations, and they often exist as compound mutations. A few reports have described the efficacy of first- and second-generation EGFR-TKIs. However, the efficacy of osimertinib in patients with these uncommon compound mutations is unknown. In this study, we reported the postoperative outcome of a patient with NSCLC and uncommon compound EGFR G719X and S768I mutations. After postoperative recurrence, the patient was treated with osimertinib, and an excellent and long-lasting clinical response was achieved. The patient has taken osimertinib for 31.0 months and exhibited a partial response, and her follow-up is ongoing.
科研通智能强力驱动
Strongly Powered by AbleSci AI